ELAB

ELEVAI Labs Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website elevaiskincare.com
Employees(FY) 18
ISIN US28622K2033

Performance

+14.8%

-39.91%

-95.81%

-97.83%

-99.3%

YTD

-99.34%

Profile

Elevai Labs Inc., a skincare development company, designs, manufactures, and markets skincare products in the United States. The company offers Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. It serves dermatologists, plastic surgeons, medical spa owners, and physicians focused on aesthetic and therapeutic skincare. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs Inc. was incorporated in 2020 and is based in Newport Beach, California.

Advanced Technical Analysis

Technical Analysis of ELAB 2024-12-20

The stock indicators reflect a mixed sentiment, with the Moving Average Score at 36 indicating a bearish outlook, while the Oscillators Score at 56 suggests a neutral stance, and the overall Technical Score at 46 reinforces a neutral sentiment. This combination implies that while there are some bearish signals, the market is not strongly negativ...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ELAB

Stock Rank

Recent News & Updates

2024-12-20 18:40
Elevai Labs plans name change to PMGC Holdings, redomicile to Nevada(Yahoo Finance)
2024-12-20 06:30
Elevai Labs Inc. Announces Name Change to PMGC Holdings Inc. and Redomicile to Nevada(Globenewswire)
2024-12-19 18:30
Elevai Labs Inc. Announces Anticipated Name Change to PMGC Holdings Inc. and Redomicile to Nevada(Globenewswire)
2024-12-08 19:00
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation(Globenewswire)
2024-12-05 18:30
Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches S-Series Root Renewal System, Marking Entry into Hair Care Market(Globenewswire)
2024-12-03 19:00
Elevai Labs Inc. Announces Record-Breaking Sales Month in 2024 for Elevai Skincare Division(Globenewswire)
2024-11-22 18:23
Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance(GlobeNewswire)
2024-11-22 17:00
Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess(GlobeNewswire)
2024-11-22 05:23
Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance(Globenewswire)
2024-11-22 04:00
Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess(Globenewswire)
2024-11-17 09:29
Elevai Labs Third Quarter 2024 Earnings: US$0.068 loss per share (vs US$0.078 loss in 3Q 2023)(Simply Wall St.)
2024-11-14 14:35
CORRECTION - Elevai Labs Inc.(GlobeNewswire)
2024-11-14 09:08
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update(GlobeNewswire)
2024-11-14 01:35
CORRECTION - Elevai Labs Inc.(Globenewswire)
2024-11-13 20:08
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update(Globenewswire)
2024-11-04 17:45
Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange(GlobeNewswire)
2024-11-04 04:45
Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange(Globenewswire)
2024-10-22 09:54
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity(GlobeNewswire)
2024-10-21 21:54
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity(Globenewswire)
2024-10-21 07:30
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity(GlobeNewswire)
2024-10-20 19:30
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity(Globenewswire)
2024-10-04 05:08
Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock(Globenewswire)
2024-10-03 03:45
REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations(Globenewswire)
2024-10-02 19:30
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations(Globenewswire)
2024-10-01 20:30
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medical Aesthetic Energy Device(Globenewswire)
2024-09-26 09:42
Altium Capital Management LP Acquires New Stake in Elevai Labs Inc(Yahoo Finance)
2024-09-24 05:00
Univest Securities, LLC Announces Closing of $8.0 Million Registered Follow-on Offering for its Client Elevai Labs Inc. (NASDAQ: ELAB)(Globenewswire)
2024-09-22 20:45
Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering(Globenewswire)
2024-09-09 19:30
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications(Globenewswire)
2024-09-02 19:30
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology(Globenewswire)

Page 1 of 3

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.